Research Reports

Healthcare

icon
Home » Reports » Insulin Management System Market
Market Research Report

Insulin Management System Market By Product Type (Needle and syringe, Insulin Pen Injectors, Insulin jet injectors, External Insulin pumps, Implantable pumps, Insulin patches); By Mode of Action (Rapid acting insulin, Short acting insulin, Intermediate acting insulin, Pre-mixed insulin); By Diabetes Type (Diabetes I, Diabetes II, Gestational Diabetes); By End User (Specialty diabetic clinics, Home care setting, Non- Diabetic Clinics) - Global Demand Analysis & Opportunity Outlook 2027

Published On : 01:14 AM, 3rd July, 2018 REP-ID-915 Category: Healthcare

Insulin Managements Market Overview

Around 194 million people around the world have diabetes, and the World Health Organization estimates the number of incidences to reach 366 million by the year 2030. Insulin is the most vital and a natural pre-prohormone manufactured by INS gene (insulin gene) by islets of langerhans in pancreas by letting body to take up glucose as energy source. Insulin averts hyperglycemia and maintains blood sugar levels in synchronization with glucagon. Frederick B and John M were Nobel Prize winners in 1923 in Medicine for the discovery of Insulin. This served as a breakthrough in history of diabetes management as the death rate owing to diabetes considerably decreased after its discovery. Diabetes is a most common health problem causing high blood sugar level resulting into excessive thirst and large amount of urine production. It sources secondary health related complications for instance hyperosmolar hyperglycemic states, diabetic ketoacidosis and other severe complications such as heart attack, stroke, leg amputation, kidney failure leading to premature death.

Market Size & Forecast

Rising prevalence of types of diabetes worldwide is adding to the growth of the global insulin management system market. The insulin management system market is thus estimated to expand at a robust CAGR over the forecast period. Insulin therapy for Type II diabetes grasps major share owing to its elevated occurrence and also accessibility to variety of advances in insulin management systems available to treat type II diabetes.

In contrast to recombinant human insulin there is bigger share for insulin analogues owing to its better efficiency with quick and long-term effects. Also in comparison to sore conventional approaches of insulin dispersion by injections, usage of inhaled insulin is predicted to have larger share in insulin management system market. Inhaled insulin is easy to dispense, acts fast and is expelled from body in less time. Thus, Insulin that is affordable, easily accessible, effortless to administer, acts fast with long-term effect and fast removal from body is estimated to grip sturdy position in insulin management system market.

Insulin Management System Market Size

On the basis of regional platform, global insulin managements market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.

North and Latin America rules the global insulin management system market owing to greater frequency of diabetes, higher earning population and also due to significant patent protection for brands of bio-similar insulin. Europe bears second largest insulin management system market owing to enhanced distribution of network for major players in insulin management system market.

Asia Pacific and MEA (Middle East and Africa) are growing rapidly owing to adoption of numerous developments in insulin management system. Initiatives taken up by government in developing countries to deliver improved healthcare facilities and easy utilization of insulin management system plays a greater role in increasing market for insulin management systems.

Market Segmentation

Our-in depth analysis of the Global Insulin managements market includes the following segments:

By Product Type

  • Needle and syringe.
  • Insulin Pen Injectors.
  • Insulin jet injectors.
  • External Insulin pumps.
  • Implantable pumps.
  • Insulin patches.
  • Islet cell transplantation.
  • Insulin inhalers

By Mode of Action

  • Rapid acting insulin.
  • Short acting insulin.
  • Intermediate acting insulin.
  • Pre-mixed insulin

By Route of Administration

  • Intravenous
  • Subcutaneous
  • Jet Spray Injectors
  • Intraperitoneal
  • Others (Oral, Inhaled)

By Diabetes Type

  • Diabetes I
  • Diabetes II
  • Gestational Diabetes

By End-User

  • Speciality diabetic clinics.
  • Home care setting.
  • Non- Diabetic Clinics

By Region

Global Insulin managements Market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of Asia) Market size, Y-O-Y growth & Opportunity Analysis.
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Insulin Management System Market

Growth Drivers & Challenges

World Diabetes Foundation has estimated that, there will be 438 million people with diabetes by 2030 which infers requirement for insulin management system market will attend escalating diabetes population. Insulin management system displays a promising market growth owing to high worldwide existence and occurrence, wide-range research and development in technology for efficient insulin delivery systems and support from government and health care centers in making insulin management systems available all over the world. According to WHO (World Health Organization) since 1980 till present, the worldwide occurrence of diabetes in adult population has increased from 4.7% to 8.5%. While in past ten years the occurrence of Diabetes in low and middle income countries is greater than in higher income countries.

Also, according to research carried out in University of Florida it was found that the deaths of children with type I diabetes is due to insufficient access to Insulin management systems owing to its high costs.

Thus, absence of low-priced or inexpensive insulin management system can impede its market growth while its obtainability would upsurge market size and demand in low and middle income countries.

Key Players

  • Eli Lilly and Company
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • GlaxoSmithKline
  • Biocon
  • Sanofi Aventis
  • Julphar
  • Novo Nordisk
  • SemBioSys
  • WOCKHARDT
  • Abbott India Ltd.
  • USV Limited
  • Torrent Pharmaceuticals Ltd
  • Piramal Enterprises Limited

Scope & Context

Overview of the Parent Market

Analyst View

Segmentation

The Global Spine Device Market is segmented as follows:

  • By Product Type Market Size & Y-O-Y Growth Analysis
  • By Mode of Action Market Size & Y-O-Y Growth Analysis
  • By Route of Administration Market Size & Y-O-Y Growth Analysis
  • By Diabetes Type Market Size & Y-O-Y Growth Analysis 
  • By End-User Market Size & Y-O-Y Growth Analysis
  • By Region Market Size & Y-O-Y Growth Analysis

Market Dynamics

Supply & Demand Risk

Competitive Landscape

Porter’s Five Force Model

Geographical Economic Activity

Key Players (respective SWOT Analysis) and their Strategies and Product Portfolio

Recent Trends and Developments

Industry Growth Drivers and Challenges

Key Information for Players to establish themselves in current dynamic environment

key Answers

SELECT LICENSE TYPE

KEY BENEFITS

  • DIRECT ANALYST ASSISTANCE

    Direct access to analyst to help you understand the market in a better way to handle your critical question

  • CUSTOMIZE AS PER YOUR NEED

    Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved

  • DISCOUNT ON CUSTOMISATION

    Get 10% free customization

  • QUALITY ASSURED

    Great focus on accuracy and quality of the research

Connect With Us

Call us

(U.S.) - +1 646 586 9123
(Canada) - +1 437 889 3230
(U.K.) - +44 203 608 5919
(India) - + 91 120 660 5495
Email: info@researchnester.com

Ask The Analyst

Delivery Center

Ansal Corporate Park, Plot no 7A/1,
Tower A1,
Sector 142 Noida., 201301 India
info@researchnester.com

US Office

77 Water Street 8th Floor,
New York, New York, 10005
Phone : +1 646 586 9123
info@researchnester.com

Canada (Toronto)

Phone : +1 437 889 3230
info@researchnester.com

UK Office (London)

Phone : +44 203 608 5919
info@researchnester.com

Copyright © 2018 Research Nester. All rights reserved

Top